couter

BOLDBoundless Bio, Inc.

Health CarePharmaceuticals
Oct 20, 2026 — Anticipated Secondary Equity Offering
Chart by TradingView

The schedule

  • Tue20Oct

    Expected dilutive capital raise to address the near-term liquidity cliff.

  • Wed4Nov

    Quarterly financial update with heavy focus on capital structure and cash runway.

  • Tue15Dec

    Early safety and pharmacokinetic data readout for the RNR inhibitor program.

  • Tue5Jan

    Interim clinical update on the lead ecDNA-directed CHK1 inhibitor program.

  • Sun14Feb

    Year-end financial results detailing 2027 clinical milestone guidance.

  • Thu15Apr

    Feedback from the FDA regarding registrational paths for BBI-355.

  • Fri7May

    Q1 financial print evaluating structural cash needs against clinical progress.

  • Fri6Aug

    Mid-year financial results and potential update on strategic alternatives.